EN DE
STOCK COMPARISON

Eli Lilly and vs Senores Pharmaceuticals L: Fair Value & Quality

Both stocks run through our valuation models. Here is how Eli Lilly and (LLY) and Senores Pharmaceuticals L (SENORES) compare, as of Oct 2, 2026.

As of Oct 2, 2026, Fair Value Calculator sees Eli Lilly and as the less overvalued of the two: Eli Lilly and trades at $1,150 versus a fair value of $749 (−34.9%), while Senores Pharmaceuticals L trades at ₹1,350 versus ₹375 (−72.2%).
Eli Lilly and
LLY · USD · Health Care
−34.9%
upside to fair value
overvalued
Price$1,150
Fair Value$749
Quality67/100
Senores Pharmaceuticals L
SENORES.NSE · INR · Health Care
−72.2%
upside to fair value
overvalued
Price₹1,350
Fair Value₹375
Quality43/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

Eli Lilly andSenores Pharmaceuticals L
Valuation
37.6×P/E (TTM)46.5×
n/aP/E ex one-offs (FY2026)51.1×
24.2×Forward P/E (FY2027)n/a
46.8×Median P/E at FY-end (9 FY, reported earnings)n/a
12.90×P/S (TTM)9.33×
38.73×P/B6.32×
25.5×EV/EBITDA35.9×
1.14×PEGn/a
−34.9%Fair value upside−72.2%
0.6%Dividend yieldn/a
$6.46Dividend per sharen/a
Profitability
54.2%Operating margin21.8%
1.42×EBIT margin trend (5Y)2.44×
102.3%Return on equity13.8%
20.4%Return on assets6.1%
Growth
47.7%Revenue growth (YoY)53.4%
31.7%Avg. growth/yr (3Y)161.6%
21.6%Avg. growth/yr (5Y)n/a
+26.6%Value creation/yrn/a
Balance & size
37.3×Interest coverage (EBIT/interest)5.5×
1.54×Debt / equity0.21×
$1.0TMarket cap$613M
mixedGrowth qualityexpensive
The P/E excluding one-off items is only shown where the special items are documented in the accounts (our own raw data or SEC filings). If one side lacks it, the reported P/E stays scored.
Eli Lilly and, median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings: 46.8.
Forward P/E: price divided by the analyst consensus for the first fiscal year that has not started yet. The current year carries special items from quarters already reported.

Eli Lilly and leads: 7 to 5 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Eli Lilly andof which business quality 64 · market factors 74 Senores Pharmaceuticals Lof which business quality 43 · market factors 73
ProfitabilityMargins and returns on capital today
85
49
Quality GrowthAre margins and returns improving?
86
75
CashflowEarnings quality: real cash, not paper profit
51
11
Fin. StrengthBalance sheet, leverage, solvency risk
53
65
InvestmentDisciplined investing over empire-building
15
0
Low VolatilityCalm price path (market factor)
79
45
MomentumPrice trend over the last 3–12 months (market factor)
66
82
52W MomentumDistance to the 52-week high (market factor)
82
88
Net IssuanceShare count: buybacks or dilution?
86
50

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyEli Lilly andPrice $1,150Senores Pharmaceuticals LPrice ₹1,350
DCF Models−70.0%below the price$345n/a
Earnings-Based−79.2%below the price$239−35.0%below the price₹877
Dividend Discount−90.0%below the price$115n/a
Multiples−68.9%below the price$358−66.7%below the price₹450
Asset-Based−98.3%below the price$19.94−89.9%below the price₹136
Growth DCF−82.9%below the price$197n/a
Economic Profit−79.4%below the price$237−86.5%below the price₹183
Growth Earnings−67.4%below the price$375−13.8%close to the price₹1,164
Minimum−98.3%below the price$19.94−89.9%below the price₹136
Maximum−67.4%below the price$375−13.8%close to the price₹1,164
Median−79.3%below the price$238−66.7%below the price₹450
Geometric mean−84.2%below the price$182−69.7%below the price₹409

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Eli Lilly and: 26 of 26 models see the stock below the current price.

Senores Pharmaceuticals L: 14 of 14 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Eli Lilly and
Price $1,150
Fair Value $749
Bear $401Bull $974
Senores Pharmaceuticals L
Price ₹1,350
Fair Value ₹375
Bear ₹271Bull ₹483

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Eli Lilly and · Health Care

Quality score67 · Top 25%
Fair value upside−34.9% · below median

Senores Pharmaceuticals L · Health Care

Quality score43 · below median
Fair value upside−72.2% · bottom 25%

Bottom line

As of Oct 2, 2026, Fair Value Calculator sees Eli Lilly and as the less overvalued of the two: Eli Lilly and trades at $1,150 versus a fair value of $749 (−34.9%), while Senores Pharmaceuticals L trades at ₹1,350 versus ₹375 (−72.2%).

Eli Lilly and has the higher quality score (67/100).

Open Eli Lilly and live analysis →
Eli Lilly and · Senores Pharmaceuticals L

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Eli Lilly and

Eli Lilly and vs UnitedHealth GroupMicrosoft vs NvidiaApple vs MicrosoftMicrosoft vs Taiwan Semiconductor Manufacturing

Related to Senores Pharmaceuticals L

Alphabet Inc Class C vs Meta PlatformsBroadcom vs MicrosoftMicrosoft vs Micron TechnologyAdvanced Micro Devices vs Microsoft
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.